Jenoptik (JEN) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
12 May, 2026Executive summary
Order intake surged 74.4% year-over-year to €356.9 million, driven by major orders in semiconductor and OEM businesses, setting a new record and boosting backlog to €719.2 million.
Revenue was €241.2 million, down 1% year-over-year, but would have been up 2% excluding FX effects; profitability improved with EBITDA up 22.5% to €44.4 million and margin rising to 18.4%.
Earnings per share rose to €0.29 from €0.16, and net profit after taxes increased to €16.8 million.
Free cash flow declined to €15.9 million due to higher working capital needs from accelerating order intake and inventory build-up.
Financial position remains strong with net debt reduced to €313.0 million and equity ratio at 60.4%.
Financial highlights
Book-to-bill ratio rose sharply to 1.48; order backlog increased to €719.2 million.
Gross margin improved to 35.4% from 30.9% year-over-year, driven by lower cost base and strong semiconductor business.
EBIT margin improved to 10.7% from 6.9% in Q1.
Functional cost ratio at 24.7%, R&D expense ratio at 6.7%, and leverage (net debt/EBITDA) stable at 1.6x.
Working capital ratio increased to 31.8% from 29.1% at year-end 2025.
Outlook and guidance
FY 2026 revenue expected to grow at a single-digit percentage rate versus prior year (€1,046.0 million), with EBITDA margin guidance set at 19.0–21.0%.
CapEx for 2026 expected to be slightly below last year’s €77.4 million; major capacity expansion in Jena to come online in 2027.
Guidance assumes stable political and economic conditions; management does not expect Q1's high order intake to persist.
Outlook remains cautious due to macroeconomic and geopolitical uncertainties.
Latest events from Jenoptik
- 2026 guidance targets single-digit revenue growth and higher margins after a challenging 2025.JEN
German Select VII Conference15 Apr 2026 - 2026 outlook targets profitable growth, led by semi and defense, after a challenging 2025.JEN
Q4 20259 Apr 2026 - 2025 saw lower revenue but improved cash flow, with growth expected to resume in 2026.JEN
Investor presentation25 Mar 2026 - Revenue and earnings up, 2024 guidance confirmed amid robust semiconductor demand.JEN
Q2 20241 Feb 2026 - Revenue and EBITDA rose, but 2025 targets postponed to 2026 amid industry delays.JEN
Q3 202415 Jan 2026 - Revenue and profit fell in H1 2025, with guidance cut amid ongoing global uncertainties.JEN
Q2 20256 Jan 2026 - 2024 saw strong growth and margins, but 2025 outlook is cautious amid persistent uncertainties.JEN
Q4 20243 Dec 2025 - Revenue and EBITDA fell, but free cash flow and order intake improved amid market uncertainty.JEN
Q3 202512 Nov 2025 - Revenue and profit fell, but Biophotonics and cash flow improved; outlook remains cautious.JEN
Q1 20256 Jun 2025